Ropivacaine liposomal (Taiwan Liposome Company)

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameRopivacaine liposomal (Taiwan Liposome Company)
Drug Alias NameTLC590TLC-590
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Lipid
Mechanisms of ActionSodium channel alpha subunit modulators
TargetsSodium channel alpha subunit
Therapy Area/IndicationsPain, PostoperativeHernia, InguinalHallux Valgus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTaiwan Liposome Company Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsPain, Postoperative
Inactive IndicationsHernia, InguinalHallux Valgus

Other Information

ATC CodeN/A
Related LinksN/A